CLINICAL TRIAL TO EVALUATE THE PREVENTION OF EVENTS WITH ANGIOTENSINCONVERTING ENZYME INHIBITOR THERAPY NIH GUIDE, Volume 23, Number 37, October 21, 1994 RFP AVAILABLE: NHLBI-HC-94-31 P.T. 34 Keywords: Cardiovascular Diseases Enzymes Inhibitors Clinical Trial National Heart, Lung, and Blood Institute The National Heart, Lung, and Blood Institute (NHLBI) is soliciting proposals for a clinical trial center to determine whether or not the addition of an angiotensin converting enzyme (ACE) inhibitor to standard therapy in patients with known coronary artery disease and preserved left ventricular function will prevent cardiovascular mortality and reduce the risk of experiencing a myocardial infarction. Other secondary endpoints will also be studied. A minimum of 14,000 patients will be enrolled. The anticipated period of performance is eight years beginning on or about August 1, 1995. The Request for Proposal (RFP) NHLBI-HC-94-31 will be released on or about October 17, 1994 with proposals due on December 5, 1994. One award is anticipated from this RFP. INQUIRIES Requests must be in writing, cite RFP NHLBI-HC-94-31, and be addressed to: Ms. Peggy Mills ECA Contract Section National Heat, Lung, and Blood Institute Federal Building, Room 200 7550 Wisconsin Avenue Bethesda, MD 20892 .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |